BANK OF AMERICA CORPORATION (Public, NYSE:BAC)
http://www.bankofamerica.com
Bank of America Corporation (Bank of America) is a bank holding company and a financial holding company. Through its banking subsidiaries and various non-banking subsidiaries throughout the United States and in selected international markets, it provides a diversified range of banking and non-banking financial services and products through three business segments: Global Consumer and Small Business Banking, Global Corporate and Investment Banking and Global Wealth and Investment Management. Bank of America operates in 50 states, the District of Columbia and more than 40 foreign countries. Bank of America has 6,100 banking centers, approximately 18,700 automated teller machines (ATMs), nationwide call centers, and online and mobile banking platforms. On January 1, 2009, Bank of America announced the purchase of Merrill Lynch & Co., Inc. On July 1, 2008, Bank of America completed the acquisition of Countrywide Financial Corporation.

CITIGROUP INC. (Public, NYSE:C)
http://www.citigroup.com 
Citigroup Inc. (Citigroup) is a global diversified financial services holding company. The Company is engaged in providing a range of financial services to consumers and corporate customers. As of May 4, 2009, Citigroup had more than 200 million customer accounts and did business in more than 140 countries. Through its two operating units, Citicorp and Citi Holdings, Citigroup provides consumers, corporations, governments and institutions with a range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, and wealth management.In August 2009, the Company sold three credit card portfolios.

CELL THERAPEUTICS Inc. (NASDAQ:CTIC)
http://www.celltherapeutics.com
Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.

NOVAVAX, INC. (Public, NASDAQ:NVAX)
http://www.novavax.com/
Novavax, Inc. (Novavax) is a clinical-stage biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon preventive options for a range of infectious diseases. These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology. VLPs are genetically engineered three-dimensional nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax’s VLPs resemble the virus but lack the genetic material to replicate the virus. Its production technology uses insect cells rather than chicken eggs or mammalian cells. The Company’s product targets include vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, Varicella Zoster, which causes shingles, and respiratory syncytial virus (RSV). This RSV vaccine was announced on October 30, 2008.

BRISTOL MYERS SQUIBB CO. (Public, NYSE:BMY)
http://www.bms.com 
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children’s nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc.

IMMUNOMEDICS, INC. (Public, NASDAQ:IMMU)
http://www.immunomedics.com/
Immunomedics, Inc. is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. It has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications. Epratuzumab’s advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). It has retained the rights for epratuzumab in oncology indications, subject to UCB’s buy-in option, and is advancing trials in lymphoma and in childhood acute lymphoblastic leukemia (ALL), in cooperation with National Cancer Institute Study Groups.

ANTIGENICS, INC.  (Public, NASDAQ:AGEN)
http://www.antigenics.com 
Antigenics Inc. (Antigenics), is a biotechnology company focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. The Company’s principal product candidate is Oncophage (vitespen), a patient-specific therapeutic cancer vaccine. Oncophage has been tested in Phase III clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in Phase I and Phase II clinical trials in a range of indications and is in a Phase II clinical trial in recurrent glioma, a type of brain cancer. The Company’s product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), which is used in numerous vaccines, AG-707, a therapeutic vaccine program for the treatment of genital herpes and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas

SPECTRUM PHARMACEUTICALS, INC. (Public, NASDAQ:SPPI)
http://www.spectrumpharm.com
Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company’s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

BRAINSTORM CELL THERAPEUTICS INC (Public, OTC:BCLI)
http://www.brainstorm-cell.com 
Brainstorm Cell Therapeutics Inc. (Brainstorm) is a development-stage company. The Company is engaged in developing stem cell therapeutic products based on technologies enabling the in-vitro differentiation of bone marrow stem cells to neural-like cells. The Company focuses on utilizing the patient’s own bone marrow stem cells to generate neurotrophic factors (NTF) cells that may provide treatment for amyotrophic lateral sclerosis (ALS), parkinson’s disease (PD) and spinal cord injury. The Company’s technology is based on the NurOwn products, an autologous cell therapeutic modality, consisting of the extraction of the patient bone marrow, processed into neuronal-like cells and re-implanted into the patient’s muscles or brain.

HUMAN GENOME SCIENCES (Public, NASDAQ:HGSI)
http://www.hgsi.com 
Human Genome Sciences (HGS)is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. Albuferon and LymphoStat-B are progressing toward commercialization. In December 2008, the Company reported that Albuferon met its primary endpoint in the first of two Phase III clinical trials in chronic hepatitis C. HGS also has several drugs in earlier stages of clinical development for the treatment of cancer, led by its TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.

OCULUS INNOVATIVE SCIENCES, INC. (Public, NASDAQ:OCLS)
http://www.oculusis.com 
Oculus Innovative Sciences, Inc. is a biopharmaceutical company that develops, manufactures and markets a family of products, based on its platform technology called Microcyn, intended to help prevent and treat infections in chronic and acute wounds. Microcyn is a non-irritating oxychlorine compound designed to treat a range of pathogens, including viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin-resistant Enterococcus (VRE), in wounds. Its device product is cleared for sale in the United States as a 510(k) medical device for wound cleaning, debridement, lubricating, moistening and dressing; is a device under Conformite Europeenne (CE) Mark in Europe; is approved by the State Food and Drug Administration (SFDA), in China as a technology that reduces the propagation of microbes in wounds and creates a moist environment for wound healing, and is approved as a drug in India and Mexico.

UNICREDIT (BIT:UCG)
http://www.unicreditgroup.eu 
UniCredit SpA is Italy-based holding company engaged in the financial sector. The Company’s division model is based on four business areas: Network Management Divisions; Centralized Product, Key Business Functions; Global Service Factories, and Multi-Local Approach. The Network Management Divisions consist of the retail markets, corporate and private banking. Its Centralized Product, Key Business Functions include markets and investment banking, asset management, leasing, household financing, global transaction banking, and retail marketing and segments. The Global Service Factories provide, among others back office, credit collection, procurement services and real estate for supplying network management divisions and product factories with specialized services. The Multi-Local Approach focuses on the relations between local banks and clients. It operates in 22 European countries through the local banks, and it also has offices and representatives in Asia and the United States.

ARENA AGROINDUSTRIE ALIMENTARI SpA (Public, BIT:ARE)
http://www.arenaholding.it 
ARENA Agroindustrie Alimentari SpA is an Italy-based food producer for large retailers. Arena Agroindustrie Alimentari SpA is active in the food sector, mainly in the poultry sector. It concentrates its activity on the marketing of fresh poultry products. The Company has four subsidiaries: Arena Alimentari Freschi SpA, Co dis al Srl, Gelus NV and Interfin SpA.

AEDES SpA (Public, BIT:AE)
http://www.aedes-immobiliare.com 
Aedes SpA is an Italy-based real estate company. It is a co-investor and management company focused on two areas of business: property services and co-investments. The property services business includes management of property funds, carried out through two savings management companies: Aedes BPM Real Estate SGR SpA and Aedes Value Added SGR, and provision of property services, carried out through five companies: Aedes Servizi SpA, Aedes Project Srl, Aedes Agency Srl, Agora Srl and Unicenter Srl. It also provides a tailor-made management service at every stage of any real estate project, with an integrated range of services: asset management, fund management, advisory, development, project management, planning engineering, intermediation, shopping mall management and financial, administrative and corporate government services.

GABETTI PROPERTY SOLUTIONS SpA (Public BIT:GAB)
http://www.gabetti.it/
Gabetti Property Solutions SpA, is a real estate holding company engaged in the planning, development, construction, management, sale and leasing of real estate properties in Italy. The Company operates through four main business lines: Agency, with Gabetti Agency SpA and Tree Real Estate Srl, consisting in direct real estate agencies, for the corporate, fractioning, and luxury sectors, and in a franchising network for the retail sector. Finance, with Tree Finance Srl, for credit brokerage services in the retail, corporate, and insurance sectors; Technical Services, with the Abaco group and Patrigest SpA, for services in the due diligence, property and facility management, consulting & advisory, ITC services B2B, energy efficiency certifications, real estate valuation and advisory, feasibility studies, and market analysis sectors; and Investment & Property, with La Gaiana SpA, for real estate trading and development investment activities, in Italy and abroad.

GEMINA SpA (Public, BIT:GEM)
http://www.gemina.it/
GEMINA Generale Mobiliare Interessenze Azionarie SpA (GEMINA) is an Italy-based investment holding company. The Company’s activities are structured of investments in the companies from four segments: airport activities; electric energy; air traffic control system, and others. In the airport activities segment, GEMINA is present by direct interests held in Aeroporti di Roma SpA (95.76%) , which manages airports in Rome. In the electric energy sector, it operates through the interests held in Sistemi di Energia SpA (45.55%). In the air traffic control system segment, the Company is active through interests held in S.I.T.T.I. SpA (40%). The company is present also in other sector through interests held in Pentar SpA (20.35%).

PRAMAC S.p.A. (Public, BIT:PRA)
http://www.pramac.com 
Pramac SpA is an Italy-based company engaged in the manufacturing of the power generation equipment, materials handling equipment and photovoltaic components. The Company divides its activities into three business sectors: Power, which comprises generators for electric power, including low voltage portable generators and medium and high voltage generators; Handling, which includes the manufacturing and distribution of the machinery for handling logistic; and Ecopower for the photovoltaic components. The Company has six production plants in Italy, Spain, France, China, the USA and Switzerland. It operates worldwide through the distribution network of subsidiaries among which are: Pramac France SAS, Pramac Lifter GmbH, Pramac Group Scandinavia Aps, Pramac Lifter Afrique Trading Sarl, Masons Power Generators Ltd and Pramac Swiss SA, among others.